Home > Result Summaries: Compounds > ropinirole > Result Summary for 101468/170

Result Summary for 101468/170

Result Summary

Protocol ID:	101468/170
Clinical Study ID:	101468/170
Official Title:	A follow-up study to observe the long term outcome of Parkinson’s disease in patients who completed Study SK&F 101468/056 or Study SK&F 101468/125.
Phase:	Phase 4
Study Indications or Diseases:	Parkinson Disease
Generic Name:	ropinirole
Trade/Product Name:	Modutab,ZIPEREVE,ZEPREVE,REPREVE,ADARTREL,REQUIP,Zygara
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Reduced dyskinesia with ropinirole in a naturalistic, 8.5-year follow-up of patients with early Parkinson’s disease (PD) who had initially received ropinirole or l-dopa Rascol O, De Deyn PP, Watts RL, Korczyn AD, AE Lang, on behalf of the 170 Study Group International Congress of Parkinson’s Disease and Movement Disorders, Rome, Italy, Jun 13–17 2004 Mov Disord 2004; 19(suppl 9): S253: P722 Incidence of Dyskinesia in a 10-yr Follow-Up of Patients with Early Parkinson's Disease (PD) Initially Receiving Ropinirole Compared with L-dopa Amos D. Korczyn, Tel Aviv, Israel, Peter P. De Deyn, Antwerp, Belgium, Olivier Rascol, Toulouse, France, Anthony Lang, Toronto, ON, Canada American Academy of Neurology, Miami Beach, USA, 9–16 Apr 2005 An 8.5-year follow-up of patients with early Parkinson’s disease initially receiving ropinirole or l-dopa. Rascol O, De Deyn PP, Watts RL, Korczyn AD, Lang AE European Federation of Neurological Societies, Helsinki, Finland, Aug 30–Sep 2 2003 Eur J Neurol 2003; 10(suppl 1): 18: SC201 Incidence of dyskinesias in a 10-year naturalistic follow-up of patients with early Parkinson’s disease (PD) initially receiving ropinirole compared with l –dopa O Rascol, AD Korczyn, P De Deyn, A Lang 9th International Congress of Parkinson’s Disease and Movement Disorders, New Orleans, USA, 5–8 March 2005 5-year follow-up REAL-PET study in patients with early Parkinson’s disease (PD) initially receiving ropinirole or l-dopa R Watts, A Lang, O Rascol, W Poewe, J Stoessl, R Hauser 9th International Congress of Parkinson’s Disease and Movement Disorders, New Orleans, USA, 5–8 March 2005 Mov Disord 2005; 20(Suppl 10): S133